Pharmaceuticals
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission ofRN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi-valent siRNA into clinical de...
2025-12-17 21:00
4029
Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administ...
2025-12-17 16:10
3847
Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2025-12-17 09:00
3489
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Ph...
2025-12-17 08:00
1671
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesit...
2025-12-15 21:00
3103
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, in...
2025-12-15 17:00
9082
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...
2025-12-15 15:02
2840
Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder
SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, out...
2025-12-15 12:40
3947
TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally
TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as th...
2025-12-12 00:21
3379
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-bindin...
2025-12-11 23:57
4129
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...
2025-12-11 14:12
2967
Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World
HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southernChina, carrying profound historical heritage and unique clinical value.The Seventh World Hakka Entrepreneurs Conven...
2025-12-11 08:00
2022
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...
2025-12-11 03:30
2458
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk
Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals")
and Formation Bio
2025-12-10 22:05
6464
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at theUniversity of Rocheste...
2025-12-10 21:00
3052
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 ...
2025-12-10 17:15
3844
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day inShanghai. The event focused on the latest advancements in the field of antibody-drug c...
2025-12-10 14:20
2702
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
SHANGHAI, Dec. 10, 2025 /PRNewswire/ -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a$108 million Series B financing round. The funding round was backed by a distinguished group ...
2025-12-10 09:30
3524
Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights
* Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential * Synergistic and complementary to Lee's Pharm's existing products pipeline, and * Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global ...
2025-12-10 08:00
3649
Inheritance + Innovation + Development: The "Co-development" Path of Hakka Medicine and Traditional Chinese Medicine
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- From November 23 to 25, the Seventh World Hakka Entrepreneurs Convention was held in Meizhou,Guangdong. The conference, with the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development," upheld the principles of "openness, innovati...
2025-12-09 08:00
1864
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
6426
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
6394
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6104
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6054
